RE: Valuation13 Apr 2020 23:38
I do find it a little too coincidental that the time frame of the deal with the outbreak. FLT +3 was shelved a couple of years ago from memory. They must have had a cause to purchase. The negotiations would not have taken a couple of weeks. I would hazard a guess of a commencement at least 3 to 4 months ago. These negotiations are not done overnight! It would be interesting to find out who approached who, Sar are not going to be walking around with a sign saying FLT+3 up for grabs. Hubei Medical University will have a hell of a lot of inside information on it.
Novacyt were 6p in November, I tried to get some Wednesday and Thursday last week at around 190p but no Internet and after 40 mins on phone to broker still in a queue, They hit a peak of over 500p a share. As regards to Novocyt and testing. it is all well and good finding out who has and who has not got it but it don't help those that end up in hospital on a ventilator. If a treatment can be found to prevent or limit the damage to lung efficiency then not only can it be used for this particular virus but also similar SARS viruses in the future. In addition there is this 9 month time frame for royalty payments all part of a jigsaw which will see as time progresses. The problem in China is far from anywhere near being under control in my estimation. It just does not add up at only 3000 fatalities.
I have a few shares in Avacta and if they continue to creep up will sell some and stick some more into SAR.
I cannot however, see SAR being in a position to produce a vaccine or have much involvement in developing one at this time,at this period in time.
Regards
SOG